Research Site
Freiburg im Breisgau, Germany
NCT Number: NCT00501605
Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Freiburg im Breisgau, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AstraZeneca
Industry
A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04374877
Adenocarcinoma, Advanced Solid Tumor
Duarte, California, United States
View Trial DetailsNCT06470763
Advanced Solid Tumor
Detroit, Michigan, United States
View Trial DetailsNCT06403436
Adult Disease, Adult Solid Tumor
Nashville, Tennessee, United States
View Trial DetailsNCT03239145
Adnexal Diseases, Advanced Solid Tumor
Boston, Massachusetts, United States
View Trial Details